Literature DB >> 23496304

Can maternal serum placental growth factor estimation in early second trimester predict the occurrence of early onset preeclampsia and/or early onset intrauterine growth restriction? A prospective cohort study.

Sanjib Kumar Ghosh1, Shashi Raheja, Anita Tuli, Chitra Raghunandan, Sneh Agarwal.   

Abstract

AIM: To determine whether maternal serum placental growth factor (PlGF) estimation in early second trimester (20-22 weeks of gestation) can predict the occurrence of early onset preeclampsia and/or early onset intrauterine growth restriction (IUGR).
MATERIAL AND METHODS: A prospective cohort study was conducted on 722 women with singleton pregnancies, screened from the antenatal clinic, and serum PlGF levels were estimated at 20-22 weeks of gestation. A cut-off value of <155 pg/mL for serum PlGF was determined by receiver operating characteristic (ROC) curve analysis for identifying pregnant women at risk of developing early onset preeclampsia and/or early onset IUGR. Preeclampsia and IUGR were classified as early onset when diagnosed by 32 weeks of gestation. Univariate logistic regression analysis was used to analyze the association between serum PlGF level <155 pg/mL and the two outcome measures (i.e. early onset preeclampsia and early onset IUGR) and odds ratio (OR) was computed. P-value < 0.05 was considered statistically significant.
RESULTS: Maternal serum PlGF level <155 pg/mL at 20-22 weeks of gestation had a strong association with early onset preeclampsia (OR 8.35; 95% CI 1.79-18.94; P = 0.007) and with early onset IUGR (OR 10.73; 95% CI 4.08-20.23; P = 0.000). The sensitivity of serum PlGF < 155 pg/mL for predicting early onset preeclampsia and early onset IUGR were 82 and 84, respectively.
CONCLUSION: Maternal serum PlGF level estimation in early second trimester (20-22 weeks of gestation) may be useful in predicting the occurrence of early onset preeclampsia and/or early onset IUGR.
© 2013 The Authors. Journal of Obstetrics and Gynaecology Research © 2013 Japan Society of Obstetrics and Gynecology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23496304     DOI: 10.1111/jog.12006

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  5 in total

1.  Noninvasive detection of trophoblast protein signatures linked to early pregnancy loss using trophoblast retrieval and isolation from the cervix (TRIC).

Authors:  Rani Fritz; Hamid-Reza Kohan-Ghadr; Jay M Bolnick; Alan D Bolnick; Brian A Kilburn; Michael P Diamond; Sascha Drewlo; D Randall Armant
Journal:  Fertil Steril       Date:  2015-06-11       Impact factor: 7.329

2.  Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria.

Authors:  H Lehnen; N Mosblech; T Reineke; A Puchooa; I Menke-Möllers; U Zechner; U Gembruch
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-05       Impact factor: 2.915

3.  Altered Biomarkers in Trophoblast Cells Obtained Noninvasively Prior to Clinical Manifestation of Perinatal Disease.

Authors:  Jay M Bolnick; Hamid-Reza Kohan-Ghadr; Rani Fritz; Alan D Bolnick; Brian A Kilburn; Michael P Diamond; D Randall Armant; Sascha Drewlo
Journal:  Sci Rep       Date:  2016-09-23       Impact factor: 4.379

4.  Predictive value of miR-210 as a novel biomarker for pre-eclampsia: a systematic review protocol.

Authors:  Pooneh Nikuei; Nahid Davoodian; Iman Tahamtan; Abbas Ali Keshtkar
Journal:  BMJ Open       Date:  2016-09-28       Impact factor: 2.692

5.  Serum biomarkers combined with uterine artery Doppler in prediction of preeclampsia.

Authors:  Lijie Li; Yanmei Zheng; Ying Zhu; Jianchun Li
Journal:  Exp Ther Med       Date:  2016-08-29       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.